- Home
- QURE vs CCCC Comparison
QURE vs CCCC Comparison
Compare QURE & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- CCCC
- Stock Information
- Founded
- QURE 1998
- CCCC 2015
- Country
- QURE Netherlands
- CCCC United States
- Employees
- QURE N/A
- CCCC N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- QURE Health Care
- CCCC Health Care
- Exchange
- QURE Nasdaq
- CCCC Nasdaq
- Market Cap
- QURE 432.6M
- CCCC 396.0M
- IPO Year
- QURE 2007
- CCCC 2020
- Fundamental
- Price
- QURE $5.85
- CCCC $4.01
- Analyst Decision
- QURE Buy
- CCCC Buy
- Analyst Count
- QURE 6
- CCCC 6
- Target Price
- QURE $17.00
- CCCC $10.00
- AVG Volume (30 Days)
- QURE 792.5K
- CCCC 1.0M
- Earning Date
- QURE 11-05-2024
- CCCC 10-31-2024
- Dividend Yield
- QURE N/A
- CCCC N/A
- EPS Growth
- QURE N/A
- CCCC N/A
- EPS
- QURE N/A
- CCCC N/A
- Revenue
- QURE $28,587,000.00
- CCCC $33,668,000.00
- Revenue This Year
- QURE $157.96
- CCCC $76.74
- Revenue Next Year
- QURE N/A
- CCCC N/A
- P/E Ratio
- QURE N/A
- CCCC N/A
- Revenue Growth
- QURE N/A
- CCCC 65.45
- 52 Week Low
- QURE $3.73
- CCCC $1.06
- 52 Week High
- QURE $11.35
- CCCC $11.88
- Technical
- Relative Strength Index (RSI)
- QURE 43.86
- CCCC 27.45
- Support Level
- QURE $5.50
- CCCC $3.84
- Resistance Level
- QURE $7.96
- CCCC $6.20
- Average True Range (ATR)
- QURE 0.59
- CCCC 0.49
- MACD
- QURE -0.16
- CCCC -0.19
- Stochastic Oscillator
- QURE 18.97
- CCCC 6.34
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.